Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPGM | P07738 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 7/20 | 0.36 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.34 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3744972 | 0.87 | PPARD (0.39) | BPGMPPARDPPARAPPARGALDH1A1 | |
| SCHEMBL3752165 | 0.85 | PPARD (0.37) | BPGMFFAR1PPARDPPARAPPARG | |
| SCHEMBL3747886 | 0.83 | PPARD (0.40) | BPGMFFAR1PPARDPPARAPPARG | |
| SCHEMBL3748585 | 0.83 | BPGM (0.37) | BPGMFFAR1CHRM5SLC6A3PPARD | |
| SCHEMBL3747892 | 0.79 | PLA2G2A (0.42) | BPGMFFAR1CHRM5SLC6A3PPARD | |
| SCHEMBL3743848 | 0.79 | PPARD (0.38) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL3527487 | 0.79 | TRPM8 (0.39) | BPGMALDH1A1PLA2G2APLA2G10 | |
| SCHEMBL3753664 | 0.79 | PPARD (0.36) | FFAR1PPARDPPARAPPARGALDH1A1 | |
| SCHEMBL3744980 | 0.78 | ALDH1A1 (0.38) | BPGMFFAR1CHRM5SLC6A3PPARD | |
| SCHEMBL3525618 | 0.77 | TRPM8 (0.37) | BPGMPPARDPPARAALDH1A1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931660-B1 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | claimed |
| EP-1931660-B1 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| EP-1931660-B1 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| US-7834030-B2 | Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-7834030-B2 | Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-7834030-B2 | Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1931660-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039178-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | GPR119, CPT1A, PC | BPGM 924/4885FFAR1 19/4885CHRM5 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.